Zunveyl® (benzgalantamine) – New drug approval

- On July 29, 2024, Alpha Cognition announced the FDA approval of Zunveyl (benzgalantamine), for the treatment of mild to moderate dementia of the Alzheimer's type in adults.
- Zunveyl is an acetylcholinesterase inhibitor and a prodrug of galantamine.
- The efficacy of Zunveyl is based upon 3 bioavailability studies in healthy adults comparing galantamine immediate-release tablets and galantamine extended-release capsules to Zunveyl.
- Warnings and precautions for Zunveyl include serious skin reactions, anesthesia, cardiovascular conditions, gastrointestinal conditions, genitourinary conditions, neurological conditions, and pulmonary conditions.
- The most common adverse reactions (≥ 5%) with Zunveyl use were nausea, vomiting, diarrhea, dizziness, headache, and decreased appetite.
- The recommended starting dose of Zunveyl is 5 mg orally twice a day (10 mg/day). Dose should be increased to initial maintenance dosage of 10 mg twice daily (20 mg/day) after a minimum of 4 weeks, based on clinical response and tolerability. Dosage may be increased to the maximum recommended dosage of 15 mg twice a day (30 mg/day) after a minimum of 4 weeks at 10 mg twice daily.
- Aimmune Therapeutics plans to launch Zunveyl in the first quarter of 2025. Zunveyl will be available as a 5 mg, 10 mg, and 15 mg delayed-release tablets.